Optimizing timing and cost-effective use of plasma biomarkers in Alzheimer's disease.
Journal:
Alzheimer's research & therapy
Published Date:
Aug 20, 2025
Abstract
BACKGROUND AND OBJECTIVES: Early and cost-effective identification of amyloid positivity is crucial for Alzheimer's disease (AD) diagnosis. While amyloid PET is the gold standard, plasma biomarkers such as phosphorylated tau 217 (pTau217) provide a potential alternative. This study evaluates the diagnostic accuracy of a combined-panel approach using machine learning models and evaluated the biomarker significance.